Etavopivat, an oral erythrocyte pyruvate kinase activator, is being developed for sickle cell disease and other hemoglobinopathies, previously reported in 2019.
Molecular Weight:
457.50
Purity:
>98.5%
CAS Number:
[2245053-57-8]
Formula:
C22H23N3O6S
Target:
Pyruvate Kinase
* VAT and and shipping costs not included. Errors and price changes excepted
